Delivery Order SPE2DP20D0002-SPE2DP25F109T
Award Date 9/8/25
Potential Completion Date 9/23/25
Potential Value $661K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. This firm-fixed-price contract, issued without a set-aside designation, supports the Medical Supply Chain within the Department of Defense. The delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus Type 4...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- The U.S. Defense Logistics Agency (DLA) awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $317,609.46 Delivery Order contract for the supply of Adenovirus Type 4 vaccines. This order falls under DLA Troop Support Medical's larger portfolio of contracts supporting military immunization programs. The contract has a firm fixed-price, with a completion date of June 25, 2024. Teva Pharmaceuticals USA, Inc. is a major supplier of critical drugs and...
- This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer. The contract, valued at $990,941.58, is for the delivery of Adenovirus Type 4 vaccine, which is used in military immunization programs. The contract has an ultimate completion date of May 20, 2025. Teva Pharmaceuticals USA, Inc. has established itself as a key supplier to federal healthcare programs,...
- The U.S. government agency Defense Logistics Agency (DLA) Troop Support Medical awarded a $158,804.73 firm-fixed-price delivery order contract to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This delivery order is part of a larger contract vehicle, and Teva has received multiple prior delivery orders for this vaccine to support military immunization programs. Teva also holds several significant Indefinite...
- This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, with a ceiling value of $330,313.86, is for the delivery of Adenovirus Type 4 vaccine to support military immunization programs. The contract has an ultimate completion date of April 29, 2025. Teva Pharmaceuticals USA, Inc. is the prime contractor, and there are no...